09
May
Toronto, May 9, 2025 — In a groundbreaking development, Canadian researchers have launched the world’s first clinical trial using a custom-designed ultrasound helmet to treat Amyotrophic Lateral Sclerosis (ALS) by opening the blood-brain barrier a natural defense that typically blocks medications from reaching the brain. Led by scientists at Sunnybrook Health Sciences Centre, the study is exploring whether the combination of intravenous immunoglobulin (IVIG) and focused ultrasound can deliver inflammation-reducing drugs directly into affected areas of the brain. “We’re creating a temporary therapeutic window,” said Dr. Lorne Zinman, co-investigator and ALS clinic director at Sunnybrook. “It’s a first in ALS…